PT  - JOURNAL ARTICLE
AU  - Cassandra Calabrese
AU  - Prabalini Rajendram
AU  - Gretchen L. Sacha
AU  - Leonard Calabrese
TI  - Practical aspects of targeting IL-6 in COVID-19 disease
AID  - 10.3949/ccjm.87a.ccc018
DP  - 2020 May 14
TA  - Cleveland Clinic Journal of Medicine
4099  - http://www.ccjm.org/content/early/2020/10/07/ccjm.87a.ccc018.short
4100  - http://www.ccjm.org/content/early/2020/10/07/ccjm.87a.ccc018.full
AB  - Interleukin 6 (IL-6) took center stage as a therapeutic target, given its role in the cytokine storm phase of COVID-19. While IL-6 inhibitors have been widely used to treat a variety of immune-mediated disease states, they have not been used often in the intensive care setting, and new data question their efficacy. This brief review provides practical information on their administration and safety.